No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
TPST240816P2500
- 0.69
- +0.19+38.00%
15min DelayClose Jul 22 16:00 ET
0.90High0.69Low
0.70Open0.50Pre Close6 Volume112 Open Interest2.50Strike Price463.00Turnover131.85%IV3.72%PremiumAug 16, 2024Expiry Date0.62Intrinsic Value100Multiplier25DDays to Expiry0.07Extrinsic Value100Contract SizeAmericanOptions Type-0.7398Delta0.5040Gamma2.69Leverage Ratio-0.0040Theta-0.0012Rho-1.99Eff Leverage0.0016Vega
Intraday
- 5D
- Daily
News
Express News | Tempest Therapeutics Files For Mixed Shelf Of Up To $300M
Express News | Tempest Therapeutics Files for Mixed Shelf of up to $300 Mln - SEC Filing
Tempest Therapeutics(TPST.US) Officer Buys US$73,850 in Common Stock
$Tempest Therapeutics(TPST.US)$ Officer Brady Stephen R purchased 35,000 shares of common stock on Jul 3, 2024 at an average price of $2.11 for a total value of $73,850. Source: Announcemen
Tempest Therapeutics(TPST.US) Officer Buys US$9,951.36 in Common Stock
$Tempest Therapeutics(TPST.US)$ Officer Whiting Samuel purchased 4,672 shares of common stock on Jul 2, 2024 at an average price of $2.13 for a total value of $9,951.36.Source: Announcement What is st
Tempest Therapeutics(TPST.US) Officer Buys US$16,200 in Common Stock
$Tempest Therapeutics(TPST.US)$ Officer Trojanowski Justin purchased 7,500 shares of common stock on Jun 28, 2024 at an average price of $2.16 for a total value of $16,200.Source: Announcement What is
Tempest and SnapSea Announce Strategic Partnership
Collaboration to enhance destination marketing, boost engagement and drive visitation with advanced user-generated content solutions PHILADELPHIA,, July 1, 2024 /PRNewswire/ -- Tempest, a leader in w
Comments
$Tempest Therapeutics(TPST.US$ Officer Brady Stephen R purchased 35,000 shares of common stock on Jul 3, 2024 at an average price of $2.11 for a total value of $73,850.![]()
2
Tempest Therapeutics to Unveil New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma.
Tempest Therapeutics, Inc., a clinical-stage biotechnology company listed on Nasdaq under the ticker TPST, is poised to release new data from its global randomized Phase 1b/2 combination study involving amezalpat (TPST-1120) in conjunction with atezolizumab and bevacizumab. This ...
Tempest Therapeutics, Inc., a clinical-stage biotechnology company listed on Nasdaq under the ticker TPST, is poised to release new data from its global randomized Phase 1b/2 combination study involving amezalpat (TPST-1120) in conjunction with atezolizumab and bevacizumab. This ...
$Tempest Therapeutics(TPST.US$ The people panicking obviously are not read in on the company or don't understand pretty much All the leadership bought between $500k-$1.7Mil in share's at approximately $9! They have not sold yet! or your a Shot playing typical Shot hedge bets. But that a dangerous bet based on current very positive results and the lack of support below $1.90! They may sell but probably won't be more than needed to fully fund them though phase 3😉
2
2
$Tempest Therapeutics(TPST.US$ goodbuy or goodbye?
4
Read more